Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
cancer
7
×
detroit blog main
detroit top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
7
×
seattle blog main
7
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
national
cancer immunotherapy
clinical trials
eli lilly
startups
deals
fda
merck
abbvie
alzheimer's disease
bristol-myers squibb
celgene
investing
What
companies
7
×
bio
roundup
life
drug
science
week
biotechs
ipo
latest
nash
new
news
price
sciences
therapeutics
admits
ago
alzheimer’s
approval
approved
arena’s
big
biogen’s
biopharmaceutical
black
bounty
cig
classes
club
combinator
comeback
continue
continued
convo
corner
crop
deals
debut
delivered
Language
unset
Current search:
companies
×
cancer
×
" san francisco top stories "
×
" seattle blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M